HoLISTIC Abstracts
Clinical prognostication in the SWOG1826 randomized clinical trial of Nivolumab-AVD versus Brentuximab-AVD: Performance of the Advanced-stage Hodgkin lymphoma international prognostic index (A-HIPI).
Casulo C, Li H, Herrera AF, Castellino SM, Rutherford SC, Davison K, Punnett A, Kahl B, Leonard JP, Smith SM, Song JY, Kelly KM, Friedberg JW, LeBlanc M, Parsons SK, Rodday A, Evens AM.
Oral presentation at the American Society of Hematology 67th annual meeting. Orlando, FL. December 2025.
External Validation of the Early-Stage Classic Hodgkin Lymphoma International Prognostication Index (E-HIPI) in the German Hodgkin Study Group (GHSG) Unfavorable Clinical Trials
Rodday AM, Eichenauer D, Jablonski J, Borchmann S, Tighiouart H, Upshaw JN, Hodgson DC, Maurer MJ, Counsell N, Rossetti S, Cui Z, Advani R, Andre M, Federico M, Hay AE, Hoppe RT, Hutchings M, Johnson P, Link B, Mou E, Savage KJ, Radford J, Cerhan J, Borchmann P, Evens AM, Parsons SK.
Presented at the American Society of Hematology 67th annual meeting. Orlando, FL. December 2025.
PET-adaptive BEACOPP- versus ABVD-based therapies for advanced-stage (AS) classic Hodgkin lymphoma (cHL): Survival comparisons leveraging a multi-state model and analyzing the impact of A-HIPI scores across the disease course
Cui Z, Rodday AM, Tighiouart H, Counsell N, Rossetti S, Upshaw J, Kirkwood A, Li H, Advani R, Casasnovas O, Cerhan J, Federico M, Gallamini A, Ghesquieres H, Hawkes E, Hodgson D, Hutchings M, Johnson P, Link B, Mou E, Radford J, Savage K, Stephens D, Zinzani PL, Maurer M, Rossi C, Evens A, Parsons S.
Oral presentation at the American Society of Hematology 67th annual meeting. Orlando, FL. December 2025.
Creation of a multistate model to improve prognostication across the disease course in advanced stage classic Hodgkin lymphoma (cHL): A Report from the HoLISTIC Consortium.
Rodday AM*, Parsons SK* (*co-first authors), Cui ZJ, Xiang Q, Counsell N, Rossetti, Upshaw JN, Williams ALM, Kirkwood AA, Li H, Cerhan JR, Federico M, Friedberg JW, Gallamini A, Hawkes EA, Hodgson D, Johnson P, Link BK, Mou E, Radford J, Savage KJ, Stephens DM, Zinzani PL, Maurer MJ, Evens AM.
Accepted for oral presentation, 66th annual meeting of the American Society of Hematology. San Diego, CA. December 2024.
Identification of Risk Categories and Stratification from the Advanced-Stage Hodgkin Lymphoma (AS-HL) International Prognostic Index (A-HIPI) Model.
Maurer M, Parsons SKP, Upshaw J, Rodday AM, Friedberg, JW, Gallamini A, Federico M, Hawkes E, Hodgson D, Johnson P, Mou E, Savage K, Zinzani PL Evens A.
Presented at the International Symposium on Hodgkin Lymphoma (ISHL13). Cologne, Germany. October 2024.
Exploring the capability of the Advanced-Stage Hodgkin Lymphoma International Prognostic Index to predict the lack of an early complete metabolic response in a multicentric Italian cohort.
Cellini A, Assanto GM, Romano A, Santuccio G, Vitale C, Montalbano MC, Cavarretta CA, Angotzi F, Ruocco V, Serafin A, Danesin N, Coscia M, Di Raimondo F, Giudice ID, Piazza F, Trentin L, Visentin A.
Presented at the International Symposium on Hodgkin Lymphoma (ISHL13). Cologne, Germany. October 2024.
Development and validation of the Early stage (ES) classic Hodgkin Lymphoma (cHL) International Prognostication Index (E-HIPI): an individualized prediction model for progression-free survival (PFS) utilizing objective and continuous variables.
Rodday AM, Radford J, Maurer M.J, Upshaw J, Counsell N, Rossetti S, Advani R, Andre M, Chang C, Gallamini A, Hay AE, Hodgson DC, Hoppe R, Hutchings M, Johnson P, Mou E, Opat S, Raemaekers J, Savage KJ, Xiang Q, Parsons SK, Evens AM.
Presented at the International Symposium on Hodgkin Lymphoma (ISHL13). Cologne, Germany. October 2024.
Identification of Risk Categories from the Advanced-Stage Hodgkin International Prognostic Index (A-HIPI) Model: A Detailed Analysis from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium
Maurer MJ, Parsons SK, Upshaw J, Friedberg JW, Gallamini A, Federico M, Hawkes EA, Hodgson D, Johnson P, Link BK, Savage KJ, Zinzani PL, Evens AM
Blood (2023) 142 (Supplement 1): 3067-3069.
External Validation of the Advanced-Stage Hodgkin Lymphoma International Prognostic Index (A-HIPI): Strong Calibration in the Brazilian Prospective Hodgkin Lymphoma Registry
Biasoli I, Buccheri V, Moreira FR, Castro N, Vilarim CC, Traina F, Chiattone C, Praxedes M, Solza C, Perobelli L, Baiocchi O, Gaiolla R, Boquimpani C, Sola CB, Silva RO, Ribas AC, Pagnano K, Steffenello G, De Souza C, Spector N, Rodday AM, Upshaw J, Maurer MJ, Evens AM, Parsons SK
Blood (2023) 142 (Supplement 1): 6200-6202.
Development and Validation of the Early-Stage Hodgkin Lymphoma (HL) International Prognostication Index (E-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium
Evens AM, Rodday, AM, Maurer MJ, Advani RH, Andre M, Gallamini A, Hay AE, Hodgson D, Hoppe RT, Hutchings M, Johnson P, Link BK, Opat S, Raemaekers JM, Upshaw J, Xiang Q, Counsell N, Parsons SK, Radford J
Blood (2023) 142 (Supplement 1): 3058-3060.
Age-Based Validation of the Advanced-Stage Hodgkin Lymphoma International Prognostic Index (A-HIPI) in a Real-World Danish Study: Suboptimal Performance in Older Patients
Jørgensen RRK, Eloranta S, Christensen JH, Hutchings M, Dahl-Soerensen RB, Kamper P, Evens AM, Maurer MJ, Parsons SK, Rodday AM, Upshaw J, El-Galaly TC, Jakobsen LH
Blood (2023) 142 (Supplement 1): 4455-4456.
Development and Validation of the advanced-Stage Hodgkin Lymphoma (HL) International Prognostication Index (A-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium
Rodday AM, Parsons SK, Friedberg JW, Gallamini A, Hawkes E, Hodgson DC, Johnson P, Link BK, Mou E, Savage KJ, Upshaw J, Zinzani PL, Maurer MJ, Evens AM
Blood (2022) 140 (Supplement 1): 760–762.
BACKGROUND
Patient and Disease Factors Predict Risk of 1-Year Mortality Among Older Adults Who Receive Intensive Chemotherapy for Hodgkin Lymphoma (HL).
Kumar AJ, Nelson J, Rodday AM, Evens AM, Friedberg JW, Wildes TM, Parsons SK.
Presentation at 62nd American Society of Hematology (ASH) Annual Meeting & Exposition. December 2020.
The Role of Immortal Time Bias in Assessing the Relationship between Treatment Intensity and Survival in Hodgkin Lymphoma: An Analysis of Surveillance, Epidemiology and End Result (SEER) Medicare Data.
Rodday AM, Hahn T, Kumar AJ, Lindenauer PK, Friedberg JW, Evens AM, Parsons SK.
Accepted at Academy Health Annual Research Meeting, June 2020
An intergroup collaboration for advanced stage classical Hodgkin lymphoma (cHL) in adolescents and young adults (AYA): SWOG S1826.
Castellino SM, LeBlanc ML, Herrera AF, Parsons SK, Punnet, A, Hodgson DC, Rutherford SC, Khan N, Constine LS, Davison K, Prica AA, Friedberg FW, Kelly, KM.
Accepted at the American Society of Clinical Oncology Meeting, June 2020.
Treatment with Full Chemotherapy Regimens in Older Adults with Hodgkin Lymphoma Improves 3-Year Overall Survival, but Less Than Half Receive Full Regimens.
Rodday AM, Hahn TE, Kumar AJ, Lindenauer PK, Friedberg JW, Evens AM, Parsons SK.
Blood. 2019;134(Supplement_1):1563-. doi: 10.1182/blood-Nov 2019-124141.
Disparities in First-line Treatment of Elderly Patients with Hodgkin Lymphoma: An Analysis of Surveillance, Epidemiology and End Results (SEER)-Medicare Data.
Rodday AM, Hahn T, Lindenauer PK, Friedberg J, Evens AM, Parsons SK.
Accepted for presentation at Academy Health 2019 Annual Research Meeting. Washington, DC. June 2019.
Hematopoietic Stem Cell Transplant Utilization in Relapsed/Refractory HL: A Population Level Analysis of Statewide Claims Data.
Waheed A, Rodday AM, Kumar AJ, Miller K, Parsons SK.
Blood, 132(Suppl 1), 4771-4771. doi: 10.1182/blood-2018-99-111921. Presentation at 60th American Society of Hematology (ASH) Annual Meeting & Exposition. San Diego, CA. December 2018.
The Development and Validation of an Electronic health record (EHR)-based Algorithm for Identifying Treatment Failure in Newly Diagnosed Hodgkin lymphoma (HL) treated in a US Community Oncology Setting.
Chao C, Xu L, Canizarro NT, Rodday AM, Feliciano J, Kumar AJ, Evens AM, Parsons SK.
Presentation at 60th American Society of Hematology (ASH) Annual Meeting & Exposition. San Diego, CA. December 2018. Blood, 132(Suppl 1), 2261-2261. doi: 10.1182/blood-2018-99-112225.
Patterns and Outcomes with Salvage Treatment for Hodgkin Lymphoma (HL): Real-World Analysis from the Community Oncology Setting.
Kumar AJ, Chun CR, Rodday AM, Cannizzaro NT, Rodriguez RR, Evens AM, Feliciano J, SK Parsons SK.
Presentation at International Symposium on Hodgkin Lymphoma. Cologne, Germany. October 2018.
Parental Work Limitations at Diagnosis of Advanced Stage Pediatric Hodgkin Lymphoma (HL): Results of Caregiver Work Limitations Questionnaire (CG WLQ).
Parsons SK, Lerner D, Rodday AM, Curtis R, Kelly K, Conti R, Castellino SM, Henderson TO.
Journal of Clinical Oncology. 2018; 36(15 suppl): e18927-e18927.